Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease

NCT07703436 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Grade 2 IDH1-mutant Glioma
Grade 3 IDH1-mutant Glioma
Glioma
IDH1-mutant Glioma
Oligodendroglioma
Oligodendroglioma IDH-1 Mutant and 1/p19q-codeleted
Astrocytoma IDH Mutant Grade 3
Astrocytoma IDH Mutant Grade 2

Interventions

DRUG: Safusidenib

Sponsor

Nuvation Bio Inc.